Immunology Programme, The Babraham Institute,Babraham Research Campus, Cambridge, United Kingdom; RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute (NCI), Frederick, United States
Alexander Saveliev
Immunology Programme, The Babraham Institute,Babraham Research Campus, Cambridge, United Kingdom
Fiamma Salerno
Immunology Programme, The Babraham Institute,Babraham Research Campus, Cambridge, United Kingdom
Louise S Matheson
Immunology Programme, The Babraham Institute,Babraham Research Campus, Cambridge, United Kingdom
Michael Screen
Immunology Programme, The Babraham Institute,Babraham Research Campus, Cambridge, United Kingdom
Hannah Lawson
Laboratory of Haematopoietic Stem Cell and Leukaemia Biology, Queen Mary University of London, London, United Kingdom
David Wotherspoon
Laboratory of Haematopoietic Stem Cell and Leukaemia Biology, Queen Mary University of London, London, United Kingdom
Kamil R Kranc
Laboratory of Haematopoietic Stem Cell and Leukaemia Biology, Queen Mary University of London, London, United Kingdom
To identify roles of RNA binding proteins (RBPs) in the differentiation or survival of antibody secreting plasma cells we performed a CRISPR/Cas9 knockout screen of 1213 mouse RBPs for their ability to affect proliferation and/or survival, and the abundance of differentiated CD138 + cells in vitro. We validated the binding partners CSDE1 and STRAP as well as the m6A binding protein YTHDF2 as promoting the accumulation of CD138 + cells in vitro. We validated the EIF3 subunits EIF3K and EIF3L and components of the CCR4-NOT complex as inhibitors of CD138 + cell accumulation in vitro. In chimeric mouse models YTHDF2-deficient plasma cells failed to accumulate.